From: Poor prognosis of nucleophosmin overexpression in solid tumors: a meta-analysis
Author | Year | Study region | Cancer type | NO. of patients | Age, median (range) | Male/ female | Cancer stage or grade | Percentage of high NPM Cutoff value | Follow-up months | HR and 95% CI | Quality score |
---|---|---|---|---|---|---|---|---|---|---|---|
Kazutaka Kikuta [30] | 2009 | Japan | Ewing’s sarcoma | 34 | 20(1–63) | 22/12 | Stage I-III | 23/34(68%), NA | 57.5 (8–179) | NA | 6 |
Yan Liu [3] | 2012 | China | Colon cancer | 31 | NA | 13/18 | NA | 19/31(61%), H-score ≥ 3 | NA | NA | 9 |
Shao-Jung Lo [31] | 2013 | Taiwan | Hepatocellular carcinoma | 110 | NA | 75/35 | Stage I-IV | 17/110(15%), score 3 | NA | HR: 1.92 CI (0.92–4.02) P = 0.082 | 9 |
Yong Li [25] | 2014 | China | Gastric cancer | 108 | NA | 76/32 | Stage I-IV | 57/108(53%), score 5–12 | 31(3–53) | HR: 1.970 CI (1.134–3.422) P = 0.0162 | 9 |
Ambrogio P. Londero [15] | 2014 | Italy | Ovarian serous cancer | 73 | NA | 0/73 | Stage I-IV | NA, H-score > 10 | 39(22–57) | HR: 2.98 CI (1.46–6.08) P < 0.05 | 7 |
Yu-Feng Yang [26] | 2014 | China | Colorectalcarcinomas | 161 | NA | 90/71 | Grade 1–3 | 104/161(64.6%), > 50% | 49.24 (23–81) | HR: 1.919 CI (1.056–3.488) P = 0.032 | 9 |
Jian-Guo Chen [27] | 2015 | China | Glioma | 90 | NA | 58/32 | Grade II-IV | 50/90(55.6%), H-score ≥ 5 | NA | HR: 2.380 CI (1.149–4.929) P = 0.020 | 9 |
Yen-Hsin Kuo [32] | 2015 | Taiwan | Astrocytoma | 99 | NA | 51/48 | Grade I-IV | 51/99(51.5%), > 50% | NA | NA | 9 |
Yi Zhu [28] | 2015 | China | Pancreatic ductal adenocarcinoma | 65 | 62(34–85) | 40/25 | Grade 1,2,4 | 46/65(69%), H-score ≥ 4 | 12(0.6–87) | NA | 7 |
Fang Zhou [14] | 2016 | China | gastric cancer | 131 | 63.5(28–85) | 96/35 | Stage I-III | 86/131(66%), H-score ≥ 5 | 39(3–55) | NA | 9 |
Hai-Ping Wang [29] | 2017 | China | Bladder urothelial carcinoma | 95 | NA | 66/29 | NA | 67/95(70.5%), NA | 81.5 (60–105) | NA | 8 |